2023 annual financial data
Revolution Medicines 2023 Operating income growth
Direct answer
Operating income growth was -88.63%.
Operating income was -487,185,000 USD and net income was -436,367,000 USD.
Operating cash flow was -350,572,000 USD.
Get free Revolution Medicines email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 11,580,000 USD
- Operating income
- -487,185,000 USD
- Net income
- -436,367,000 USD
- Operating cash flow
- -350,572,000 USD